A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) ...

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in ...

Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, ...

Laxmi Patel, chief strategy officer at Savista, outlines major impacts of the “One Big Beautiful Bill” Act on Medicaid and ...

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

Among patients who have myasthenia gravis, even low disease activity can impact their quality of life (QOL) via motor ...

Lower geriatric nutritional risk index (GNRI) scores in older patients with osteoarthritis are linked to higher all-cause and cardiovascular mortality risks, highlighting the critical role of ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...

Panelists discuss how providers and payers must collaborate to develop innovative coverage criteria for BTK inhibitors that prevent patients with subclinical progression from being forced to fail ...